KPF
APGNW

K2 Principal Fund’s Apexigen, Inc. WarrantApexigen, Inc. Warrant APGNW Stock Holding History

K2 Principal Fund’s Portfolio APGNW Stock Details APGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-127,682
Closed -$51K – 409
2021
Q4 		$51K Hold
127,682
– – ﹤0.01% 353
2021
Q3 		$84K Buy
+127,682
New +$123K 0.01% 289

Other funds holding APGNW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

K2 Principal Fund's APGNW Position: Q1 2022 in Review

K2 Principal Fund sold out of Apexigen, Inc. WarrantApexigen, Inc. Warrant (APGNW) in Q1 2022, closing a stake of 127,682 shares — an estimated $51K sold.

K2 Principal Fund first reported a position in APGNW in Q3 2021 and held it in 2 quarters. The position peaked at $84K in Q3 2021. 12 funds tracked by Wall St. Rank hold APGNW as of Q1 2022.

  • K2 Principal Fund reported no remaining Apexigen, Inc. WarrantApexigen, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
  • K2 Principal Fund sold 127,682 Apexigen, Inc. WarrantApexigen, Inc. Warrant shares in Q1 2022, an estimated $51K.
  • K2 Principal Fund first reported a position in Apexigen, Inc. WarrantApexigen, Inc. Warrant in Q3 2021 and held it in 2 quarters.
  • K2 Principal Fund's Apexigen, Inc. WarrantApexigen, Inc. Warrant position peaked at $84K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Apexigen, Inc. WarrantApexigen, Inc. Warrant as of Q1 2022.

Based on K2 Principal Fund's 13F filing for Q1 2022, filed 16 May 2022.